Navigation Links
Study Published in Molecular Therapy Shows that Immune Response to FANG™ Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
Date:3/1/2012

functional short hairpin RNA construct against furin is introduced into the cells by electroporation. Cells are then incubated overnight, irradiated, frozen, QC-tested and released.  Vaccine is shipped to the patient's clinic where doses are thawed and administered monthly by intradermal injection.  FANG manufacturing is a straightforward two-day cGMP process that is applicable to nearly all tumor types with no modification, and it does not require patients to undergo apheresis or other taxing treatment protocols beyond medically-indicated surgical tumor removal.

About Gradalis, Inc.

Gradalis, Inc. is a privately-held, fully-integrated biotechnology company based in Dallas, Texas that is focused on developing, manufacturing and commercializing drugs, vaccines, tools and diagnostics primarily in the area of cancer. The company has two primary platforms:  one focused on personalized autologous vaccines and the other focused on bifunctional short hairpin RNA delivered via a proprietary lipoplex system. Gradalis has its own state of the art GMP manufacturing facility along with high-skilled technical leadership and staff, as well as a strategic partnership with Mary Crowley Cancer Research Centers for early stage clinical development of Gradalis products.  More information on the Company and its programs can be found at www.gradalisinc.com.

 


'/>"/>
SOURCE Gradalis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
2. Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups
3. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
4. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
5. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
6. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
7. Medical Device Study Examines Use of Emerging Markets and Outsourcing for Clinical Activities
8. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
9. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
10. Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
11. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015  Today, the National Mobility Equipment ... 2015 National Mobility Awareness Month Local Heroes Contest on ... online entries that received 1.3 million votes. The sponsors ... Toyota Mobility , and Valley Honda Dealers ... and Vantage Mobility International (VMI) and ...
(Date:6/30/2015)... Calif. , June 30, 2015  Avanir ... PRISM II study showing that treatment with NUEDEXTA ... reduction in symptoms of pseudobulbar affect (PBA) in ... PBA is a distressing condition characterized by sudden ... from certain neurologic diseases or brain injury. PRISM ...
(Date:6/30/2015)... Minn. , June 30, 2015  EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering  of 40,229,886 units. Each ... of a Series A warrant to purchase one share ... warrant to purchase one share of common stock, at ...
Breaking Medicine Technology:NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
(Date:6/30/2015)... Arlington, Texas (PRWEB) , ... June 30, 2015 , ... ... at some point in life. Back pain can range from a dull, constant ache ... back pain such as epidural steroid injections, selective nerve root blocks and ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... It ... the florets once in the kitchen, and discard the stalks before cooking. Throwing out ... actually can be eaten and are quite delicious. It just takes a little knowledge ...
(Date:6/30/2015)... ... ... New Xarelto lawsuit claims proposed for consolidation in the ... to attorneys handling Xarelto lawsuits included in the MDL.* The forms, ... plaintiffs’ attorneys in filing new claims, according to court documents. Drafts of these ...
(Date:6/30/2015)... BC (PRWEB) , ... June 30, 2015 , ... When ... might be that they feel the associated costs will be too high. However, there ... have the volunteer abroad experience at minimal cost. One such volunteer named ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... and operated service and repair companies in San Diego. Bill Howe offers all ... the company, through several organizations, but most notably through the local Plumbing-Heating-Cooling-Contractors of ...
Breaking Medicine News(10 mins):Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 4Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 3Health News:Volunteers Transform Themselves and Their Resumes with Medical Volunteer Placements Abroad 2Health News:Volunteers Transform Themselves and Their Resumes with Medical Volunteer Placements Abroad 3Health News:Two Local San Diego Plumbers from Bill Howe Plumbing, Inc. Graduate from PHCC Academy 2Health News:Two Local San Diego Plumbers from Bill Howe Plumbing, Inc. Graduate from PHCC Academy 3
... RICHMOND, Va., July 27 Insmed Inc. (Nasdaq: ... the Company will cease the supply of IPLEX((TM)) to any new ... trials with IPLEX((TM)) at this time. The Company has determined ... treatment of existing patients. , , ...
... , , ... will hold three (3) rallies this week to urge Congress to pass ... is being stalled because of partisanship and political infighting, the campaign seeks ... suffer daily because of escalating health care costs and sub-standard medical care. ...
... , , , ... (Nasdaq: SNSS ) today announced that Helen S. Kim ... Ms. Kim is a designee of New Enterprise Associates, which purchased ... of the company,s recent private placement. , , ...
... Emerging Therapies to Treat Metastatic Hormone-Refractory Prostate Cancer Will ... New Report from Decision Resources , , ... of the world,s leading research and advisory firms for pharmaceutical ... prostate cancer drug market though 2018 will be driven principally ...
... DENVER, July 27 Because nearly everyone struggles with medical bills, medical ... some tips on how you can best use and pay for your ... most respected companies of its type. These tips are from Andrew Graham, ... Your doctor will be more helpful to you if you are ...
... SynCare, LLC(R), an innovator in disease and case management, has been ... n a C o mp a n ... h . The 50 Companies to Watch program, created and managed by ... Small Business Development Center network and Purdue University. , , The ...
Cached Medicine News:Health News:Insmed Provides Update on Supply of IPLEX(TM) 2Health News:Insmed Provides Update on Supply of IPLEX(TM) 3Health News:Delaying Health Care Reform is U-N-A-C-C-E-P-T-A-B-L-E! 2Health News:Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors 2Health News:Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018 2Health News:Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018 3Health News:What the Medical Biller Knows (That You Should Know) 2Health News:SynCare, LLC Honored as Indiana Company to Watch 2